{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:03:26Z","timestamp":1790809406884,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004699","name":"CSMU | Chung Shan Medical University Hospital","doi-asserted-by":"publisher","award":["CSH-2019-C-026, CSH-2024-A-018, and CSH-2025-C-012"],"award-info":[{"award-number":["CSH-2019-C-026, CSH-2024-A-018, and CSH-2025-C-012"]}],"id":[{"id":"10.13039\/501100004699","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-025-01066-4","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T23:10:51Z","timestamp":1754089851000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Comparative ocular outcomes of tirzepatide versus other anti-obesity medications in people with obesity"],"prefix":"10.1038","volume":"5","author":[{"given":"Yu-Nan","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo-Ching","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin-Hung","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Yen","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Wen","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1156-9345","authenticated-orcid":false,"given":"Gideon","family":"Meyerowitz-Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4174-5036","authenticated-orcid":false,"given":"Pen-Hua","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"1066_CR1","doi-asserted-by":"crossref","unstructured":"Nowell, H. P. et al. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet 403, 1027\u20131050 (2024).","DOI":"10.1016\/S0140-6736(23)02750-2"},{"key":"1066_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.34","volume":"3","author":"P Gonz\u00e1lez-Muniesa","year":"2017","unstructured":"Gonz\u00e1lez-Muniesa, P. et al. Obesity. Nat. Rev. Dis. Prim. 3, 17034 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1066_CR3","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","volume":"143","author":"TM Powell-Wiley","year":"2021","unstructured":"Powell-Wiley, T. M. et al. Obesity and cardiovascular disease: a scientific statement From the American Heart Association. Circulation 143, e984\u2013e1010 (2021).","journal-title":"Circulation"},{"key":"1066_CR4","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1161\/CIRCRESAHA.120.316101","volume":"126","author":"ME Pich\u00e9","year":"2020","unstructured":"Pich\u00e9, M. E., Tchernof, A. & Despr\u00e9s, J. P. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ. Res. 126, 1477\u20131500 (2020).","journal-title":"Circ. Res."},{"key":"1066_CR5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.survophthal.2006.12.003","volume":"52","author":"N Cheung","year":"2007","unstructured":"Cheung, N. & Wong, T. Y. Obesity and eye diseases. Surv. Ophthalmol. 52, 180\u2013195 (2007).","journal-title":"Surv. Ophthalmol."},{"key":"1066_CR6","doi-asserted-by":"publisher","first-page":"e12616","DOI":"10.1111\/cob.12616","volume":"14","author":"S Lam","year":"2024","unstructured":"Lam, S., Lindsey, J., Carranza Leon, B. G. & Takkouche, S. Shedding light on eye disease in obesity: a review. Clin. Obes. 14, e12616 (2024).","journal-title":"Clin. Obes."},{"key":"1066_CR7","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1038\/s41366-021-00829-y","volume":"45","author":"C Ng Yin Ling","year":"2021","unstructured":"Ng Yin Ling, C., Lim, S. C., Jonas, J. B. & Sabanayagam, C. Obesity and risk of age-related eye diseases: a systematic review of prospective population-based studies. Int. J. Obes. 45, 1863\u20131885 (2021).","journal-title":"Int. J. Obes."},{"key":"1066_CR8","doi-asserted-by":"crossref","unstructured":"Russell, M. W., Kumar, M., Li, A., Singh, R. P. & Talcott, K. E. Incidence of ocular pathology following bariatric surgery for with morbid obesity across a large United States National Database. Eye 38, 2603\u20132609 (2024).","DOI":"10.1038\/s41433-024-03088-z"},{"key":"1066_CR9","doi-asserted-by":"crossref","unstructured":"Duh, E. J., Sun, J. K. & Stitt, A. W. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight. 2, e93751 (2017).","DOI":"10.1172\/jci.insight.93751"},{"key":"1066_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40519-024-01662-8","volume":"29","author":"F Bosello","year":"2024","unstructured":"Bosello, F. et al. Obesity, body fat distribution and eye diseases. Eat. Weight Disord. 29, 33 (2024).","journal-title":"Eat. Weight Disord."},{"key":"1066_CR11","doi-asserted-by":"crossref","unstructured":"Huang, Y. N. et al. Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: a global retrospective cohort study. Diabetes Obes. Metab. 26, 5222\u20135232 (2024).","DOI":"10.1111\/dom.15869"},{"key":"1066_CR12","doi-asserted-by":"crossref","unstructured":"Drucker, D. J. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diab. Care. 47, 873\u20131888 (2024).","DOI":"10.2337\/dci24-0003"},{"key":"1066_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne, L. J. et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 Randomized Clinical Trial. JAMA 331, 38\u201348 (2024).","journal-title":"JAMA"},{"key":"1066_CR14","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.cmet.2024.05.010","volume":"36","author":"A Regmi","year":"2024","unstructured":"Regmi, A. et al. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor. Cell Metab. 36, 1534\u20131549.e1537 (2024).","journal-title":"Cell Metab."},{"key":"1066_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101882","volume":"58","author":"M Chakhtoura","year":"2023","unstructured":"Chakhtoura, M. et al. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinicalMedicine 58, 101882 (2023).","journal-title":"EClinicalMedicine"},{"key":"1066_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.immuni.2021.12.013","volume":"55","author":"TV Rohm","year":"2022","unstructured":"Rohm, T. V., Meier, D. T., Olefsky, J. M. & Donath, M. Y. Inflammation in obesity, diabetes, and related disorders. Immunity 55, 31\u201355 (2022).","journal-title":"Immunity"},{"key":"1066_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/jamiaopen\/ooad035","volume":"6","author":"MB Palchuk","year":"2023","unstructured":"Palchuk, M. B. et al. A global federated real-world data and analytics platform for research. JAMIA Open 6, ooad035 (2023).","journal-title":"JAMIA Open"},{"key":"1066_CR18","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele, T. J. & Ding, P. Sensitivity analysis in observational research: introducing the e-value. Ann. Intern. Med. 167, 268\u2013274 (2017).","journal-title":"Ann. Intern. Med."},{"key":"1066_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02753-6","volume":"21","author":"D Zheng","year":"2023","unstructured":"Zheng, D. et al. Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies. BMC Med. 21, 40 (2023).","journal-title":"BMC Med."},{"key":"1066_CR20","doi-asserted-by":"publisher","first-page":"e2232584","DOI":"10.1001\/jamanetworkopen.2022.32584","volume":"5","author":"YC Su","year":"2022","unstructured":"Su, Y. C. et al. Comparison of sodium-glucose cotransporter 2 inhibitors vs glucagonlike peptide-1 receptor agonists and incidence of dry eye disease in patients with type 2 diabetes in Taiwan. JAMA Netw. Open 5, e2232584 (2022).","journal-title":"JAMA Netw. Open"},{"key":"1066_CR21","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.survophthal.2023.07.002","volume":"68","author":"I Kapoor","year":"2023","unstructured":"Kapoor, I., Sarvepalli, S. M., D\u2019Alessio, D., Grewal, D. S. & Hadziahmetovic, M. GLP-1 receptor agonists and diabetic retinopathy: a meta-analysis of randomized clinical trials. Surv. Ophthalmol. 68, 1071\u20131083 (2023).","journal-title":"Surv. Ophthalmol."},{"key":"1066_CR22","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.2337\/dc17-2280","volume":"41","author":"A Douros","year":"2018","unstructured":"Douros, A. et al. Glucagon-like peptide 1 receptor agonists and the risk of incident diabetic retinopathy. Diab. Care 41, 2330\u20132338 (2018).","journal-title":"Diab. Care"},{"key":"1066_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41433-021-01741-5","volume":"36","author":"A Sharma","year":"2022","unstructured":"Sharma, A. et al. Semaglutide and the risk of diabetic retinopathy-current perspective. Eye 36, 10\u201311 (2022).","journal-title":"Eye"},{"key":"1066_CR24","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/jdi.12450","volume":"7","author":"Y Suzuki","year":"2016","unstructured":"Suzuki, Y. et al. Anti-inflammatory role of glucose-dependent insulinotropic polypeptide in periodontitis. J. Diab. Investig. 7, 497\u2013505 (2016).","journal-title":"J. Diab. Investig."},{"key":"1066_CR25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","volume":"15","author":"F Stapleton","year":"2017","unstructured":"Stapleton, F. et al. TFOS DEWS II epidemiology report. Ocul. Surf. 15, 334\u2013365 (2017).","journal-title":"Ocul. Surf."},{"key":"1066_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1379189","volume":"11","author":"W Masson","year":"2024","unstructured":"Masson, W. et al. Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis. Front. Cardiovasc. Med. 11, 1379189 (2024).","journal-title":"Front. Cardiovasc. Med."},{"key":"1066_CR27","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/j.cmet.2024.09.003","volume":"36","author":"B Chen","year":"2024","unstructured":"Chen, B. et al. GLP-1 programs the neurovascular landscape. Cell Metab. 36, 2173\u20132189 (2024).","journal-title":"Cell Metab."},{"key":"1066_CR28","first-page":"96","volume":"5","author":"M Khorrami-Nejad","year":"2016","unstructured":"Khorrami-Nejad, M., Sarabandi, A., Akbari, M. R. & Askarizadeh, F. The impact of visual impairment on quality of life. Med. Hypothesis Discov. Innov. Ophthalmol. 5, 96\u2013103 (2016).","journal-title":"Med. Hypothesis Discov. Innov. Ophthalmol."},{"key":"1066_CR29","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jamaophthalmol.2015.5322","volume":"134","author":"CY Kauh","year":"2016","unstructured":"Kauh, C. Y., Blachley, T. S., Lichter, P. R., Lee, P. P. & Stein, J. D. Geographic variation in the rate and timing of cataract surgery among US communities. JAMA Ophthalmol. 134, 267\u2013276 (2016).","journal-title":"JAMA Ophthalmol."},{"key":"1066_CR30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ophtha.2013.10.002","volume":"121","author":"JC Erie","year":"2014","unstructured":"Erie, J. C. Rising cataract surgery rates: demand and supply. Ophthalmology 121, 2\u20134 (2014).","journal-title":"Ophthalmology"},{"key":"1066_CR31","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.ophtha.2013.04.030","volume":"120","author":"GC Brown","year":"2013","unstructured":"Brown, G. C. et al. Cataract surgery cost utility revisited in 2012: a new economic paradigm. Ophthalmology 120, 2367\u20132376 (2013).","journal-title":"Ophthalmology"},{"key":"1066_CR32","volume":"13","author":"FH Zhao","year":"2022","unstructured":"Zhao, F. H. et al. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors. Nat. Commun. 13, 16 (2022).","journal-title":"Nat. Commun."},{"key":"1066_CR33","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","volume":"58","author":"J Lau","year":"2015","unstructured":"Lau, J. et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J. Med. Chem. 58, 7370\u20137380 (2015).","journal-title":"J. Med. Chem."},{"key":"1066_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","volume":"18","author":"T Coskun","year":"2018","unstructured":"Coskun, T. et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol. Metab. 18, 3\u201314 (2018).","journal-title":"Mol. Metab."},{"key":"1066_CR35","doi-asserted-by":"crossref","unstructured":"Willard, F. S. et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 5, e140532 (2020).","DOI":"10.1172\/jci.insight.140532"},{"key":"1066_CR36","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s42255-023-00811-0","volume":"5","author":"K El","year":"2023","unstructured":"El, K. et al. The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. Nat. Metab. 5, 945 (2023).","journal-title":"Nat. Metab."},{"key":"1066_CR37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas, J. P. et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N. Engl. J. Med 385, 503\u2013515 (2021).","journal-title":"N. Engl. J. Med"},{"key":"1066_CR38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.cmet.2024.11.003","volume":"37","author":"X Yu","year":"2025","unstructured":"Yu, X. et al. The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice. Cell Metab. 37, 187\u2013204.e187 (2025).","journal-title":"Cell Metab."},{"key":"1066_CR39","doi-asserted-by":"crossref","unstructured":"Puddu, A. & Maggi, D. Anti-inflammatory effects of GLP-1R activation in the retina. Int. J. Mol. Sci. 23, 12428 (2022).","DOI":"10.3390\/ijms232012428"},{"key":"1066_CR40","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2337\/db15-0443","volume":"65","author":"C Hern\u00e1ndez","year":"2016","unstructured":"Hern\u00e1ndez, C. et al. Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. Diabetes 65, 172\u2013187 (2016).","journal-title":"Diabetes"},{"key":"1066_CR41","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1111\/dom.13339","volume":"20","author":"JB Hebsgaard","year":"2018","unstructured":"Hebsgaard, J. B. et al. Glucagon-like peptide-1 receptor expression in the human eye. Diab. Obes. Metab. 20, 2304\u20132308 (2018).","journal-title":"Diab. Obes. Metab."},{"key":"1066_CR42","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/jnr.22001","volume":"87","author":"BA Buhren","year":"2009","unstructured":"Buhren, B. A., Gasis, M., Thorens, B., M\u00fcller, H. W. & Bosse, F. Glucose-dependent insulinotropic polypeptide (GIP) and its receptor (GIPR): cellular localization, lesion-affected expression, and impaired regenerative axonal growth. J. Neurosci. Res. 87, 1858\u20131870 (2009).","journal-title":"J. Neurosci. Res."},{"key":"1066_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108271","volume":"33","author":"JK Sterling","year":"2020","unstructured":"Sterling, J. K. et al. GLP-1 receptor agonist NLY01 reduces retinal inflammation and neuron death secondary to ocular hypertension. Cell Rep. 33, 108271 (2020).","journal-title":"Cell Rep."},{"key":"1066_CR44","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ajo.2024.08.030","volume":"269","author":"S Hallaj","year":"2025","unstructured":"Hallaj, S. et al. Association between glucagon-like peptide-1 receptor agonists exposure and intraocular pressure change: GLP-1 receptor agonists and intraocular pressure change. Am. J. Ophthalmol. 269, 255\u2013265 (2025).","journal-title":"Am. J. Ophthalmol."},{"key":"1066_CR45","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834\u20131844 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1066_CR46","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/dom.13172","volume":"20","author":"T Vilsb\u00f8ll","year":"2018","unstructured":"Vilsb\u00f8ll, T. et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diab. Obes. Metab. 20, 889\u2013897 (2018).","journal-title":"Diab. Obes. Metab."},{"key":"1066_CR47","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/dom.13538","volume":"21","author":"SC Bain","year":"2019","unstructured":"Bain, S. C., Klufas, M. A., Ho, A. & Matthews, D. R. Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review. Diab. Obes. Metab. 21, 454\u2013466 (2019).","journal-title":"Diab. Obes. Metab."},{"key":"1066_CR48","doi-asserted-by":"publisher","first-page":"100168","DOI":"10.1016\/j.endmts.2024.100168","volume":"15","author":"H Stevens","year":"2024","unstructured":"Stevens, H., de la Paz, M., Cooper, B. & Bhattacharya, R. Long-term use of semaglutide and risk of diabetic retinopathy progression. Endocr. Metab. Sci. 15, 100168 (2024).","journal-title":"Endocr. Metab. Sci."},{"key":"1066_CR49","doi-asserted-by":"publisher","first-page":"102118","DOI":"10.1016\/j.molmet.2025.102118","volume":"95","author":"TD M\u00fcller","year":"2025","unstructured":"M\u00fcller, T. D. et al. Glucose-dependent insulinotropic polypeptide (GIP). Mol. Metab. 95, 102118 (2025).","journal-title":"Mol. Metab."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01066-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01066-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01066-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T12:55:53Z","timestamp":1757336153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01066-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1066"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-01066-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5493930\/v1","asserted-by":"object"}]},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"24 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare. The funders had no role in the design, execution, interpretation, or writing of this study, and the authors maintain no personal or financial relationships that could potentially influence the work presented here.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"329"}}